Be the first to like this
A high degree of unmet clinical needs, the rising prevalence of ailments such as coronary artery diseases and hypertension, as well as increasing disposable incomes are creating robust opportunities for emerging interventional cardiac devices in emerging countries. Although the U.S. and European markets will witness the highest growth, device manufacturers must focus on developing economies such as India and China, where the market is growing between 12 and 15 percent per annum.
New analysis from Frost & Sullivan’s analysis on The Global Emerging Interventional Cardiac Devices Market finds the market earned revenue of $1.49 billion in 2013 and estimates this to reach $6.93 billion in 2020. The analysis covers devices for the following segments: transcatheter heart valves, renal denervation, bronchial thermoplasty, bioresorbable stents, and fractional flow reserve.